ADVFN - Advanced Financial Network.
HOME» NASDAQ » A » ALKS Stock Price » ALKS Stock News

Alkermes Share News

 Alkermes (mm) Stock Price
ALKS Stock Price
 Alkermes (mm) Stock Chart
ALKS Stock Chart
 Alkermes (mm) Stock News
ALKS Stock News
 Alkermes (mm) Company Information
ALKS Company Information
 Alkermes (mm) Stock Trades
ALKS Stock Trades

Eli Lilly Type-1 Diabetes Drug Fails Trial Efficacy Endpoint

DOW JONES NEWSWIRES Eli Lilly & Co. (LLY) and its partner in licensing diabetes-drug candidate teplizumab said the treatment failed to reach the main efficacy goal a late-stage study. As a results, Lilly and MacroGenics Inc. suspended further enrollment and dosing of patients in two other ongoing clinical trials of the treatment effect in type-1 diabetes. Teplizumab, which the companies license from PDL BioPharma Inc. (PDLI), was being tested to treat newly diagnosed type-1 diabetes, the less-common type of the disease. The treatment was meant to slow its progression. Gwen Krivi, a Lilly executive in diabetes product development, called the drug's failure to reach the primary endpoint "obviously disappointing. She said the two companies will be considering all options for teplizumab. Under the licensing arrangement, Lilly agreed to pay PDL BioPharma fees during testing of teplizumab and would pay royalties on sales if the drug is approved. The trial results follow other another disappointment for Lilly on a diabetes drug-candidate earlier this week. The Food and Drug Administration held off on approving the company's long-acting version of diabetes drug Byetta, requesting more testing and data analysis. Eli Lilly is developing the drug with Amylin Pharmaceuticals Inc. and Alkermes Inc. (ALKS). The approval was widely expected. Lilly shares were down 0.2% at $35.95 in after-hours trading, while PDL closed the regular session Wednesday up 2.2% at $5.59 and wasn't active after the close. -By Joan E. Solsman, Dow Jones Newswires; 212-416-2291; joan.solsman@dowjones.com

Stock News for Alkermes (ALKS)
DateTimeHeadline
11/15/201309:01:37HBK Investments LP 3Q 13F: Largest Eliminations
11/15/201309:01:27HBK Investments LP 3Q 13F: Largest Eliminations -2-
11/15/201309:01:27HBK Investments LP 3Q 13F: Largest Sales
11/15/201309:01:27HBK Investments LP 3Q 13F: Largest Purchases
11/15/201308:22:25Janus Capital Management 3Q 13F: Largest Purchases -2-
11/15/201308:22:24Janus Capital Management 3Q 13F: Largest Purchases
11/15/201308:22:24Janus Capital Management 3Q 13F: Holdings As Of -2-
11/15/201308:22:23Janus Capital Management 3Q 13F: Holdings As Of Sep 30
10/10/201309:29:34U.S. Hot Stocks Futures: Hot Stocks to Watch
05/31/201209:19:14US HOT STOCK FUTURES: HOT STOCKS TO WATCH
01/30/201217:42:15US Stocks Edge Lower As Europe's Debt Flashpoints Weigh
01/30/201208:02:33US Stock Futures Lower On Renewed Worries Over Greece
01/27/201216:12:26FDA Approves Amylin's Bydureon Diabetes Drug After Delays
07/28/201109:30:07Amylin, Eli Lilly And Alkermes Submit Reply To FDA On Bydureon
07/27/201105:30:27CORRECT: Elan Confirms Outlook As Quarterly Net Loss Narrows
07/18/201115:19:27Alkermes Sees Sales Growth After Merger With Elan Drug Tech
07/12/201110:09:05Elan To Close Pennsylvania Site Ahead Of Unit Sale To Alkermes
06/24/201119:46:35Amylin, MannKind Shares Rise On Diabetes Data Releases
06/21/201107:02:05Lilly, Amylin, Alkermes Diabetes Drug Gets EU Approval
05/09/201104:46:15Elan Sells EDT Unit To Alkermes To Generate Cash, Cut Debt

Alkermes and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad